Eli Lilly and Company (BIT:1LLY)
Italy · Delayed Price · Currency is EUR | Market Cap | 695.90B +2.9% |
| Revenue (ttm) | 55.51B +44.7% |
| Net Income | 17.58B +94.9% |
| EPS | 19.55 +96.0% |
| Shares Out | n/a |
| PE Ratio | 39.59 |
| Forward PE | 25.90 |
| Dividend | 3.91 (0.50%) |
| Ex-Dividend Date | Nov 13, 2025 |
| Volume | 39 |
| Average Volume | 230 |
| Open | 782.50 |
| Previous Close | 783.90 |
| Day's Range | 768.00 - 783.00 |
| 52-Week Range | 535.20 - 972.00 |
| Beta | n/a |
| RSI | 34.37 |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Lilly's eczema drug shows durable long-term response in late-stage study
Eli Lilly said on Friday that its eczema drug showed durable results in a late-stage post-marketing study, such as relief from persistent itch for up to four years in patients with the skin condit...
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years 75% of patients achieved a high bar of near-complete skin clearanc...
The market for weight loss drugs is exploding and patients may have several new options in coming years—here's a look, in charts
The market for weight loss drugs is exploding and patients may have several new options in coming years.
What's Going On With Eli Lilly On Monday?
More than 80 global executives gathered in Beijing for the China Development Forum, signaling renewed corporate interest in the Chinese market despite ongoing geopolitical tensions.
U.S. executives, from Apple to Eli Lilly, revamp their push into the world's second-largest economy at the China Development Forum
Household names were among the more than 30 U.S. corporate executives who joined the China Development Forum in Beijing over the weekend. Fresh off a recovery in Apple iPhone sales in China, CEO Tim C...
Our Top 10 High Growth Dividend Stocks - March 2026
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
Why Eli Lilly Remains My Top Obesity Bet
Despite HSBC downgrading Eli Lilly and Company stock, it remains my favorite in the obesity treatment market. That's also because LLY's tirzepatide franchise sales grew 114.6% year-on-year to about $1...
Eli Lilly's next-generation obesity drug retatrutide clears first late-stage diabetes trial
Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug lowe...
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrutide 12 mg lost an average of 36.6 lbs (16.8%) No...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (I'd Buy Both)
Roche Holding AG has announced a major AI infrastructure expansion with Nvidia, surpassing peers in GPU deployment for drug development. RHHBY now operates over 3,500 Blackwell GPUs, positioning itsel...
Stock Of The Day: Is The Eli Lilly Selloff Over?
As you can see on the chart, in April 2025 when Eli Lilly reached the $890 level, it hit resistance. A reversal and move lower followed.
Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound's cash sales
If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.
Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations
According to Bloomberg, the downgrade (the stock's lowest on Wall Street) comes after a bit of back and forth.
4 Stocks To Buy While Everyone Else Doubts AI
Ross Gerber, CEO of Gerber Kawasaki, breaks down the 4 stocks he's buying right now — including why Micron and Nvidia are the most mispriced AI plays in the market.
Eli Lilly falls after a 6 month rally; is this a buy the dip opportunity?
Shares of Eli Lilly came under pressure on Tuesday after HSBC downgraded the stock, raising fresh questions about whether the pharmaceutical giant's strong run in the obesity drug market can continue ...
Eli Lilly Stock Gets Downgraded. It Faces Stiff Headwinds After Strong Run-Up.
Eli Lilly, the maker of Zepbound and Mounjaro, faces stiff price competition in the coming year, HSBC says.
Tuesday's Morning Movers: DAL Lifts Guidance, LLY & DKNG Downgrades
Delta Airlines (DAL) upped its revenue guidance to high single-digit growth, giving a much-needed boost to shares after airlines took a hit over Iran uncertainty. HSBC shed bullish optimism in Eli Lil...
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clear or almost clear skin (IGA 0,1) at Week 16 In key secondary endpoints, 39% of pati...
Invesco Rising Dividends Fund Q4 2025 Portfolio Activity
Linde was purchased due to its essential and resilient business model, anchored by long-term contracts and leadership in industrial gases. We sold Oracle due to concerns about downside risk as its inv...
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
Eli Lilly and Co (NYSE: LLY) on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12.
Eli Lilly: The Weight-Loss Craze Isn't Over
Eli Lilly is rated a strong buy with a $1,623 price target, driven by multiple near- and long-term catalysts. Orforglipron's Q2 launch and Medicare/Medicaid eligibility will expand LLY's addressable m...
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
British drugmaker AstraZeneca Plc (NYSE: AZN) has emerged as the leading contender to acquire French biotech Abivax SA (NASDAQ: ABVX), following the company's dramatic valuation surge after strong cli...
Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks
Compounded weight-loss drugs that contain vitamin B12 and the main ingredient in Eli Lilly's Zepbound could present health risks to consumers due to a previously unidentified impurity caused in the p...